View Post

Lung Cancer Studies From TRACERx Consortium Explore How Tumor Cells Evolve

In In The News by Barbara Jacoby

By: Staff Reporter From: genomeweb.com Blood and tumor samples might be able to differentiate lung cancer patients whose disease is likely to spread from those who won’t progress, according to three new studies. More than 218,000 people are diagnosed with lung cancer each year in the US, and less than a fifth of patients survive for more than five years. …

View Post

Startup joins Roche to hold clinical trials for double-whammy cancer drug

In Clinical Trials by Barbara Jacoby

By: Shoshanna Solomon From: imesofisrael.com DSP-107, developed by KAHR Medical, hopes to have dual impact: tag cancer cells, and boost activity of the immune cells that target them KAHR Medical, an Israeli biopharmaceutical company, says it is developing a second generation class of  immunotherapy drugs that it hopes will be more effective in tackling cancer, based on the lessons learned …

View Post

Amgen’s drug targeting ‘undruggable’ protein shines at lung cancer conference

In Clinical Trials by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com Amgen presented data for the KRAS G12C inhibitor AMG 510 at the World Conference on Lung Cancer in Barcelona, showing a 54 percent response rate among patients receiving the pivotal study dose. A drug in development for a protein target once thought unreachable by pharmaceutical means has new data showing its potential efficacy in lung …

View Post

Roche drug is third to win biomarker-driven cancer approval from FDA

In Clinical Trials by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com Another drug designed to treat cancer patients based on a genetic driver rather than where tumors occur in the body has received approval from the Food and Drug Administration. The FDA on Thursday granted Swiss drugmaker Roche’s Rozlytrek (entrectinib) approval for ROS1-positive non-small cell lung cancer and accelerated approval for solid tumors with NTRK gene …

View Post

AstraZeneca’s flagship Tagrisso helps lung cancer patients live longer in pivotal study

In Clinical Trials by Barbara Jacoby

By: Natalie Grover From: endpts.com AstraZeneca is off to a good start in August. After its PARP inhibitor Lynparza scored in a prostate cancer trial earlier this week, the British drugmaker on Friday disclosed that its star cancer drug Tagrisso helped patients with a certain type of lung cancer live longer in a late-stage study. The overall survival data follows …

View Post

Amgen Plans Pivotal Lung Cancer Trial For Its Pipeline Star

In Clinical Trials by Barbara Jacoby

Source: Andrew Dunn, BiotechDive From: pharmavoice.com Amgen stole the show at this year’s annual meeting of the American Society of Clinical Oncology with promising early data from a cancer drug designed to target KRAS mutations, an elusive target that’s frustrated decades of research efforts. Now, the biotech plans to soon advance the drug into a Phase 2 study in lung …

View Post

Mesothelioma Victims Center Now Urges a US Navy Veteran with Mesothelioma or Asbestos Exposure Lung Cancer to Call Them

In In The News by Barbara Jacoby

Source: Mesothelioma Victims Center From: prnewswire.com Mesothelioma Victims Center Now Urges a US Navy Veteran with Mesothelioma or Asbestos Exposure Lung Cancer to Call Them for Direct Access to Attorney Erik Karst to Discuss the Value of Their Compensation Claim—Especially If the Veteran Was Stationed at Norfolk-Pearl Harbor or San Diego The Mesothelioma Victims Center’s number one goal is making …

View Post

Immunotherapy for lung cancer: Researchers working to broaden its reach

In Clinical Trials by Barbara Jacoby

By: Scott Merville From: mdanderson.org Immunotherapy drugs have produced promising results in cancers like melanoma and leukemia, yet the drugs only work for 20 percent of lung cancer patients. MD Anderson researchers are working to change that. Immunotherapy drugs that free the immune system to attack cancer have provided durable responses for about 20 percent of lung cancer patients, which …

View Post

Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab

In Clinical Trials by Barbara Jacoby

At ASCO-SITC Clinical Immuno-Oncology Symposium From: digitaljournal.com – Preliminary data suggests the addition of HS-110 to Nivolumab may restore responsiveness to treatment after tumor progression on prior checkpoint inhibitor therapy – Median overall survival not yet reached with median follow up of 14.4 months in Cohort A – Improved survival observed in patients with low CD8+ “cold” tumor at baseline …

View Post

Racial disparities in US cancer deaths are shrinking, study finds

In In The News by Barbara Jacoby

Posted By: CNN Wire From: wtvr.com Racial disparities in cancer deaths between black and white patients in the United States are receding — but more progress is needed to completely close the gap for some cancer types and age groups, according to a new study. Among men, the overall cancer death rate was 47% higher for blacks than for whites …